

Supporting Information

An acid-catalyzed 1,4-addition isocyanide-based multicomponent reaction in neat water

Jie Lei,^{a,b} Yong Li,^{a,b} Jia Xu,^a Dian-Yong Tang,^a Jing-Wei Shao,^b Hong-yu Li,^{*b}
Zhong-Zhu Chen^{*a} and Zhi-Gang Xu^{*a}

^aCollege of Pharmacy, National & Local Joint Engineering Research Center of Targeted and Innovative Therapeutics, Chongqing Key Laboratory of Kinase Modulators as Innovative Medicine, Chongqing University of Arts and Sciences, Chongqing 402160, China. Email: 18883138277@163.com; xzg@cqwu.edu.cn

^bDepartment of Pharmaceutical Sciences, College of Pharmacy, University of Arkansas for Medical Sciences, Little Rock, Arkansas 72205, USA. Email: HLi2@uams.edu

Table of Contents	Page
General Experimental.....	2
General procedures for compounds 5	2
General procedures for compounds 10	2
General procedures for compounds 11	3
Control experiments.....	3-4
Acylation of compound 5a	5
NMR characterization data and figures of products.....	5-46
X-ray data	47

General Experimental

¹H and ¹³C NMR were recorded on a Bruker 400 spectrometer. ¹H NMR data are reported as follows: chemical shift in ppm (δ), multiplicity (s = singlet, d = doublet, t = triplet, m = multiplet), coupling constant (Hz), relative intensity. ¹³C NMR data are reported as follows: chemical shift in ppm (δ). LC/MS analyses were performed on a Shimadzu-2020 LC-MS instrument using the following conditions: Shim-pack VP-ODS C18 column (reverse phase, 150 x 4.6 mm); a linear gradient from 10% water and 90% acetonitrile to 75% acetonitrile and 25% water over 6.0 min; flow rate of 0.5 mL/min; UV photodiode array detection from 200 to 400 nm. High-resolution mass spectra (HRMS) were recorded on Thermo Scientific Exactive Plus System. The products were purified by Biotage Isolera™ Spektra Systems and hexane/EtOAc solvent systems. All reagents and solvents were obtained from commercial sources and used without further purification.

General procedures for compound 5.



The solution of formic acid (5 mol%, aqueous solution) was added to a mixture of aldehyde (0.3 mmol), amine (0.3 mmol) and isocyanide (0.3 mmol). Then this system was stirred in water (2.0 mL) at 100 °C for 2 h and then monitored by TLC. When the reaction was completed, the reaction mixture was diluted with EtOAc (15.0 mL), washed with sat. NaHCO₃ and brine. The organic layer was dried over MgSO₄ and concentrated. The residue was purified by silica gel column chromatography using a gradient of ethyl acetate/hexane (0-100%) to afford the relative targeted product **5**.

General procedure for compound 11


The solution of formic acid (5 mol%, aqueous solution) was added to a mixture of chromone-3-carboxaldehyde **1a** (0.2 mmol), 2-methylpropan-2-amine **2a** (0.2 mmol), 1,1,3,3-tetramethylbutyl isocyanide **3c** (0.2 mmol). Then this system was stirred in water (1.5 mL) at 100 °C for 2 h and then monitored by TLC. When the reaction was completed, the reaction mixture was concentrated under reduced pressure. In a solution of this residue in dichloromethane (DCM) (3.0 mL), [bis(trifluoroacetoxy)iodo]benzene (PIFA, 0.2 mmol) and trifluoroacetic acid (TFA, 0.2 mmol) were added and stirred at room temperature for 6 h. When the reaction was completed, the reaction mixture was diluted with EtOAc (15.0 mL), washed with sat.

Na₂CO₃ and brine. The organic layer was dried over MgSO₄ and concentrated. The residue was purified by silica gel column chromatography using a gradient of ethyl acetate/hexane (0-100%) to afford the product **11**.


Control experiments



m/z	Intensity	Relative
121.02840	24675974.0	0.14
174.05490	101199264.0	0.58
230.11754	34497744.0	0.20
331.20160	30973452.0	0.18
385.24933	39078452.0	0.22
387.26462	17416132608.0	100.00
388.26730	4454016000.0	25.57
389.27026	619520576.0	3.56
390.27338	55054208.0	0.32




20190622-180 #1005 RT: 6.71 AV: 1 NL: 1.03E10
T: FTMS + p ESI Full ms [100.0000-1000.0000]



m/z	Intensity	Relative
387.26495	751660544.0	5.87
388.26874	348332512.0	2.72
388.47635	3765759.8	0.03
389.00110	3907922.0	0.03
389.26883	12809865216.0	100.00
389.54413	4167084.3	0.03
390.05676	3746140.0	0.03
390.27167	3424700672.0	26.73
391.27271	3780219136.0	29.51


Acylation of compound 5a



A solution of chromone-3-carboxaldehyde **1a** (0.3 mmol), 2-methylpropan-2-amine **2a** (0.3 mmol), 2-isocyano-1,3-dimethylbenzene **3a** (0.3 mmol) and 1-(4-chlorophenyl)cyclopropane-1-carboxylic acid **12** (0.3 mmol) was stirred in 2,2,2-trifluoroethanol (TFE, 2.0 mL) for 2 h. The reaction mixture was monitored by TLC. When the reaction was completed, the solvent was removed under reduced pressure. Then the reaction mixture was diluted with EtOAc (15.0 mL), washed with sat. NaHCO₃ and brine. The organic layer was dried over MgSO₄ and concentrated. The residue was purified by silica gel column chromatography using a gradient of ethyl acetate/hexane (0-100%) to afford product **13** with 83% yield.


NMR Characterization Data and Figures of Products

(Z)-3-((*tert*-butylamino)methylene)-*N*-(2,6-dimethylphenyl)-4-oxochromane-2-carboxamide




5a, 94 mg, light green solid, 83% (EA/Hex = 20%, R_f = 0.3), ¹H NMR (400 MHz, CDCl₃) δ 10.85 (d, *J* = 13.1 Hz, 1H), 7.93 (dd, *J* = 7.7, 1.6 Hz, 1H), 7.67 (s, 1H), 7.47 – 7.35 (m, 2H), 7.16 – 6.96 (m, 5H), 5.50 (s, 1H), 2.04 (s, 6H), 1.34 (s, 9H). ¹³C NMR (100 MHz, CDCl₃) δ 178.81, 168.96, 156.42, 149.08, 135.33, 133.67, 132.83, 128.19, 127.56, 126.62, 123.66, 122.63, 116.53, 95.50, 78.55, 52.91, 29.99, 18.14. HRMS (ESI) *m/z* calcd for C₂₃H₂₇N₂O₃⁺ (*M*+*H*)⁺ 379.2016, found 379.2012.

***(Z)*-N-(tert-butyl)-3-((tert-butylamino)methylene)-4-oxochromane-2-carboxamide**




5b, 87 mg, light yellow solid, 88% (EA/Hex = 20%, R_f = 0.25), ¹H NMR (400 MHz, CDCl₃) δ 10.74 (d, *J* = 12.6 Hz, 1H), 7.87 (dd, *J* = 7.7, 1.7 Hz, 1H), 7.41 – 7.33 (m, 1H), 7.29 (d, *J* = 13.3 Hz, 1H), 7.10 – 7.02 (m, 1H), 6.93 (d, *J* = 8.2 Hz, 1H), 6.31 (s, 1H), 5.17 (s, 1H), 1.33 (s, 9H), 1.31 (s, 9H). ¹³C NMR (100 MHz, CDCl₃) δ 179.35, 168.87, 156.52, 148.57, 133.41, 126.48, 123.78, 122.34, 116.42, 95.96, 78.52, 52.79, 51.20, 29.99, 28.58. HRMS (ESI) *m/z* calcd for C₁₉H₂₇N₂O₃⁺ (M+H)⁺ 331.2016, found 331.2019.

***(Z)*-3-((tert-butylamino)methylene)-4-oxo-N-(2,4,4-trimethylpentan-2-yl)chromane-2-carboxamide**




5c, 80 mg, light yellow solid, 70% (EA/Hex = 20%, R_f = 0.30), ¹H NMR (400 MHz, CDCl₃) δ 10.81 (d, *J* = 13.2 Hz, 1H), 7.96 (d, *J* = 2.5 Hz, 1H), 7.43 (dd, *J* = 8.6, 2.5 Hz, 1H), 7.34 (d, *J* = 13.4 Hz, 1H), 6.82 (d, *J* = 8.7 Hz, 1H), 6.31 (s, 1H), 5.14 (s, 1H), 1.38 (s, 2H), 1.34 (s, 9H), 0.91 (s, 6H). ¹³C NMR (100 MHz, CDCl₃) δ 177.55, 168.22, 155.36, 149.27, 135.90, 129.19, 125.21, 118.35, 114.92, 95.25, 78.51, 55.29, 51.94, 31.38, 29.96, 29.12, 28.69. HRMS (ESI) *m/z* calcd for C₂₃H₃₅N₂O₃⁺ (M+H)⁺ 387.2642, found 387.2646.

***(Z)*-N-(tert-butyl)-3-(((2-methylbut-3-yn-2-yl)amino)methylene)-4-oxochromane-2-carboxamide**




5d, 88 mg, light yellow solid, 86% (EA/Hex = 20%, Rf = 0.25), ^1H NMR (400 MHz, CDCl_3) δ 10.64 (d, $J = 12.7$ Hz, 1H), 7.87 (dd, $J = 7.8, 1.7$ Hz, 1H), 7.55 (dd, $J = 12.6, 0.8$ Hz, 1H), 7.39 (ddd, $J = 8.2, 7.3, 1.8$ Hz, 1H), 7.11 – 7.02 (m, 1H), 6.95 (dd, $J = 8.2, 0.8$ Hz, 1H), 6.30 (s, 1H), 5.19 (d, $J = 0.8$ Hz, 1H), 2.49 (s, 1H), 1.60 (d, $J = 1.3$ Hz, 6H), 1.32 (s, 9H). ^{13}C NMR (100 MHz, CDCl_3) δ 180.34, 168.43, 156.81, 148.72, 133.79, 126.61, 123.56, 122.39, 116.61, 97.23, 84.85, 78.54, 73.21, 51.25, 31.26, 30.99, 28.60. HRMS (ESI) m/z calcd for $\text{C}_{20}\text{H}_{25}\text{N}_2\text{O}_3^+$ ($\text{M}+\text{H}$) $^+$ 341.1860, found 341.1857.

(Z)-3-(((2-methylbut-3-yn-2-yl)amino)methylene)-4-oxo-N-(2,4,4-trimethylpentan-2-yl)chromane-2-carboxamide




5e, 94 mg, light yellow solid, 79% (EA/Hex = 20%, Rf = 0.25), ^1H NMR (400 MHz, CDCl_3) δ 10.66 (d, $J = 12.5$ Hz, 1H), 7.90 – 7.80 (m, 1H), 7.56 (dd, $J = 12.7, 0.7$ Hz, 1H), 7.38 (ddd, $J = 8.2, 7.3, 1.8$ Hz, 1H), 7.09 – 7.00 (m, 1H), 6.93 (dd, $J = 8.2, 0.7$ Hz, 1H), 6.34 (s, 1H), 5.16 (d, $J = 0.7$ Hz, 1H), 2.49 (s, 1H), 1.59 (d, $J = 3.0$ Hz, 5H), 1.36 (d, $J = 7.7$ Hz, 6H), 0.89 (s, 9H). ^{13}C NMR (100 MHz, CDCl_3) δ 180.17, 168.26, 156.76, 148.96, 133.78, 126.61, 123.48, 122.35, 116.57, 96.98, 84.87, 78.51, 73.23, 55.19, 51.95, 51.17, 31.36, 29.14, 28.68. HRMS (ESI) m/z calcd for $\text{C}_{24}\text{H}_{33}\text{N}_2\text{O}_3^+$ ($\text{M}+\text{H}$) $^+$ 397.2486, found 397.2502.

(Z)-N-(2,6-dimethylphenyl)-3-(((2-methylbut-3-yn-2-yl)amino)methylene)-4-oxochromane-2-carboxamide




5f, 67 mg, light yellow solid, 57% (EA/Hex = 30%, R_f = 0.35), ¹H NMR (400 MHz, CDCl₃) δ 10.75 (d, *J* = 12.5 Hz, 1H), 7.93 (dd, *J* = 7.7, 1.7 Hz, 1H), 7.73 – 7.56 (m, 2H), 7.42 (ddd, *J* = 8.2, 7.4, 1.7 Hz, 1H), 7.10 – 6.99 (m, 5H), 5.52 (s, 1H), 2.50 (s, 1H), 2.04 (s, 6H), 1.60 (d, *J* = 1.9 Hz, 6H). ¹³C NMR (100 MHz, CDCl₃) δ 179.81, 168.53, 156.71, 149.25, 135.36, 134.06, 132.84, 128.18, 127.56, 126.75, 123.45, 122.68, 116.74, 96.75, 84.81, 78.54, 73.33, 51.23, 31.10, 18.19. HRMS (ESI) *m/z* calcd for C₂₄H₂₅N₂O₃⁺ (M+H)⁺ 389.1860, found 389.1861.

(Z)-N-(tert-butyl)-3-((isopropylamino)methylene)-4-oxochromane-2-carboxamide




5g, 65 mg, light yellow solid, 69% (EA/Hex = 20%, R_f = 0.25), ¹H NMR (400 MHz, CDCl₃) δ 10.41 (s, 1H), 7.87 (d, *J* = 6.6 Hz, 1H), 7.36 (dd, *J* = 11.3, 4.1 Hz, 1H), 7.18 (d, *J* = 13.0 Hz, 1H), 7.05 (t, *J* = 7.5 Hz, 1H), 6.93 (d, *J* = 8.2 Hz, 1H), 6.30 (s, 1H), 5.15 (s, 1H), 3.53 (dt, *J* = 13.2, 6.5 Hz, 1H), 1.30 (dd, *J* = 5.4, 4.7 Hz, 9H), 1.27 (d, *J* = 6.5 Hz, 6H). ¹³C NMR (100 MHz, CDCl₃) δ 179.33, 168.93, 156.50, 150.76, 133.46, 126.53, 122.34, 116.39, 95.90, 78.29, 51.23, 50.60, 28.60, 23.77, 23.57. HRMS (ESI) *m/z* calcd for C₁₈H₂₅N₂O₃⁺ (M+H)⁺ 317.1860, found 317.1861.

(Z)-3-((isopropylamino)methylene)-4-oxo-N-(2,4,4-trimethylpentan-2-yl)chromane-2-carboxamide




5h, 66 mg, light yellow solid, 60% (EA/Hex = 25%, R_f = 0.30), ¹H NMR (400 MHz, CDCl₃) δ 10.43 (d, *J* = 7.4 Hz, 1H), 7.93 – 7.78 (m, 1H), 7.36 (ddd, *J* = 8.6, 7.4, 1.7 Hz, 1H), 7.20 (d, *J* = 13.0 Hz, 1H), 7.04 (ddd, *J* = 7.4, 4.4, 0.8 Hz, 1H), 6.92 (dd, *J* = 8.2, 0.4 Hz, 1H), 6.35 (s, 1H), 5.12 (s, 1H), 3.52 (td, *J* = 13.3, 6.6 Hz, 1H), 1.65 (d, *J* = 18.8 Hz, 2H), 1.35 (d, *J* = 3.8 Hz, 6H), 1.27 (dd, *J* = 6.5, 0.8 Hz, 6H), 0.87 (s, 9H). ¹³C NMR (100 MHz, CDCl₃) δ 179.26, 168.81, 156.46, 151.06, 133.46, 126.53, 123.59, 122.31, 116.36, 95.63, 78.30, 55.17, 51.81, 50.64, 31.53, 31.33, 29.21, 28.74, 23.82, 23.54. HRMS (ESI) *m/z* calcd for C₂₂H₃₃N₂O₃⁺ (M+H)⁺ 373.2486, found 373.2486.

***(Z)*-6-bromo-*N*-(*tert*-butyl)-3-(((*tert*-butylamino)methylene)-4-oxochromane-2-carboxamide**




5i, 72 mg, light green solid, 59% (EA/Hex = 20%, R_f = 0.25), ¹H NMR (400 MHz, CDCl₃) δ 10.78 (d, *J* = 12.6 Hz, 1H), 7.97 (d, *J* = 2.5 Hz, 1H), 7.44 (dd, *J* = 8.6, 2.5 Hz, 1H), 7.31 (d, *J* = 13.4 Hz, 1H), 6.83 (d, *J* = 8.6 Hz, 1H), 6.25 (s, 1H), 5.17 (s, 1H), 1.33 (s, 9H), 1.32 (s, 9H). ¹³C NMR (100 MHz, CDCl₃) δ 177.66, 168.44, 155.39, 149.04, 135.93, 129.21, 118.38, 114.98, 95.48, 78.53, 53.03, 51.34, 29.94, 28.59. HRMS (ESI) *m/z* calcd for C₁₉H₂₆BrN₂O₃⁺ (M+H)⁺ 409.1121, found 409.1131.

***(Z)*-6-bromo-*N*-(*tert*-butyl)-3-(((2-methylbut-3-yn-2-yl)amino)methylene)-4-oxochromane-2-carboxamide**




5j, 92 mg, light yellow solid, 74% (EA/Hex = 20%, R_f = 0.25), ¹H NMR (400 MHz, CDCl₃) δ 10.67 (d, *J* = 12.5 Hz, 1H), 7.96 (d, *J* = 2.5 Hz, 1H), 7.58 (d, *J* = 12.7 Hz, 1H), 7.49 – 7.43 (m, 1H), 6.85 (d, *J* = 8.7 Hz, 1H), 6.24 (s, 1H), 5.19 (s, 1H), 2.50 (d, *J* = 0.5 Hz, 1H), 1.60 (s, 6H), 1.33 (s, 9H). ¹³C NMR (100 MHz, CDCl₃) δ 178.74, 168.02, 155.68, 149.24, 136.32, 129.31, 125.04, 118.58, 115.03, 96.67, 84.58, 78.56, 73.50, 51.40, 31.24, 30.97, 28.63. HRMS (ESI) *m/z* calcd for C₂₀H₂₄BrN₂O₃⁺ (M+H)⁺ 419.0965, found 419.0997.

(Z)-6-bromo-3-(((2-methylbut-3-yn-2-yl)amino)methylene)-4-oxo-N-(2,4,4-trimethylpentan-2-yl)chromane-2-carboxamide




5k, 112 mg, light yellow solid, 80% (EA/Hex = 30%, R_f = 0.25), ¹H NMR (400 MHz, CDCl₃) δ 10.70 (d, *J* = 12.7 Hz, 1H), 7.96 (d, *J* = 2.5 Hz, 1H), 7.60 (d, *J* = 12.7 Hz, 1H), 7.46 (dd, *J* = 8.7, 2.5 Hz, 1H), 6.84 (d, *J* = 8.7 Hz, 1H), 6.30 (s, 1H), 5.17 (s, 1H), 2.51 (s, 1H), 1.67 (s, 2H), 1.60 (d, *J* = 2.5 Hz, 6H), 1.38 (d, *J* = 9.0 Hz, 6H), 0.91 (s, 9H). ¹³C NMR (100 MHz, CDCl₃) δ 178.87, 167.83, 155.65, 149.47, 137.28, 136.30, 129.30, 128.80, 124.96, 119.73, 118.55, 114.98, 96.44, 78.54, 73.52, 55.35, 52.47, 52.01, 31.60, 30.99, 29.68, 29.11. HRMS (ESI) *m/z* calcd for C₂₄H₃₁BrN₂O₃⁺ (M+H)⁺ 475.1591, found 475.1595.

(Z)-N-(2,6-dimethylphenyl)-3-((isopropylamino)methylene)-4-oxochromane-2-carboxamide




5l, 78 mg, white solid, 71% (EA/Hex = 30%, Rf = 0.25), ^1H NMR (400 MHz, CDCl_3) δ 10.44 (d, $J = 11.7$ Hz, 1H), 7.93 (dd, $J = 7.8, 1.5$ Hz, 1H), 7.66 (s, 1H), 7.40 (ddd, $J = 8.3, 7.4, 1.1$ Hz, 1H), 7.26 (dd, $J = 13.6, 6.8$ Hz, 2H), 7.13 – 7.02 (m, 4H), 5.48 (s, 1H), 3.53 (dq, $J = 13.3, 6.7$ Hz, 1H), 2.03 (s, 6H), 1.28 (dd, $J = 6.5, 3.7$ Hz, 6H). ^{13}C NMR (100 MHz, CDCl_3) δ 179.02, 168.94, 156.47, 151.15, 135.31, 133.75, 132.80, 128.19, 127.55, 126.68, 123.61, 122.64, 116.56, 95.52, 78.44, 50.74, 23.72, 23.62, 18.12. HRMS (ESI) m/z calcd for $\text{C}_{22}\text{H}_{25}\text{N}_2\text{O}_3^+$ ($\text{M}+\text{H}$) $^+$ 365.1860, found 365.1865.

(Z)-6-bromo-N-(tert-butyl)-3-((isopropylamino)methylene)-4-oxochromane-2-carboxamide




5m, 82 mg, white solid, 69% (EA/Hex = 20%, Rf = 0.35), ^1H NMR (400 MHz, CDCl_3) δ 10.45 (d, $J = 21.3$ Hz, 1H), 7.96 (d, $J = 2.5$ Hz, 1H), 7.44 (dd, $J = 8.6, 2.5$ Hz, 1H), 7.23 (d, $J = 13.4$ Hz, 1H), 6.82 (d, $J = 8.7$ Hz, 1H), 6.30 (s, 1H), 5.12 (d, $J = 0.4$ Hz, 1H), 3.54 (td, $J = 13.3, 6.6$ Hz, 1H), 1.36 (d, $J = 5.6$ Hz, 6H), 1.28 (d, $J = 6.5$ Hz, 6H), 0.90 (s, 9H). ^{13}C NMR (100 MHz, CDCl_3) δ 178.50, 169.19, 156.22, 152.30, 136.82, 130.09, 125.97, 119.20, 115.80, 96.05, 79.19, 56.19, 52.74, 51.64, 32.44, 32.23, 30.06, 29.61, 24.61, 24.37. HRMS (ESI) m/z calcd for $\text{C}_{18}\text{H}_{24}\text{BrN}_2\text{O}_3^+$ ($\text{M}+\text{H}$) $^+$ 395.0965, found 395.0961.

(Z)-N-butyl-3-((tert-butylamino)methylene)-4-oxochromane-2-carboxamide




5n, 35mg, yellow solid, 36% (EA/Hex = 20%, Rf = 0.3), ^1H NMR (400 MHz, CDCl_3) δ 10.78 (d, J = 13.7 Hz, 1H), 7.87 (d, J = 7.8 Hz, 1H), 7.40 – 7.28 (m, 2H), 7.05 (t, J = 7.5 Hz, 1H), 6.94 (d, J = 8.2 Hz, 1H), 6.42 (s, 1H), 5.28 (s, 1H), 3.25 (ddd, J = 29.6, 13.4, 6.8 Hz, 2H), 1.48 – 1.43 (m, 2H), 1.25 (s, 9H), 1.20 (d, J = 7.2 Hz, 2H), 0.84 (dd, J = 8.0, 6.7 Hz, 3H). ^{13}C NMR (101 MHz, CDCl_3) δ 179.02, 169.97, 156.48, 148.86, 133.48, 126.50, 123.58, 122.34, 116.35, 95.58, 52.82, 38.99, 31.46, 29.98, 29.66, 29.39, 19.81, 13.62. HRMS (ESI) m/z calcd for $\text{C}_{19}\text{H}_{27}\text{N}_2\text{O}_3^+$ ($\text{M}+\text{H}$) $^+$ 331.2016, found 331.2014.

***(Z)*-N-benzyl-3-((*tert*-butylamino)methylene)-4-oxochromane-2-carboxamide**




5o, 45 mg, yellow solid, 42% (EA/Hex = 20%, Rf = 0.3), ^1H NMR (400 MHz, cdcl_3) δ 10.78 (d, J = 13.5 Hz, 1H), 7.89 (d, J = 8.1 Hz, 1H), 7.40 – 7.24 (m, 6H), 7.11 (d, J = 6.8 Hz, 1H), 7.06 (t, J = 7.4 Hz, 1H), 6.91 (d, J = 8.0 Hz, 1H), 6.78 (s, 1H), 5.36 (s, 1H), 4.57 – 4.38 (m, 2H), 1.33 (s, 9H). ^{13}C NMR (101 MHz, CDCl_3) δ 170.09, 156.44, 148.83, 137.69, 133.57, 128.66, 127.45, 1127.28, 126.53, 123.99, 122.43, 116.50, 95.49, 52.86, 43.06, 29.53. HRMS (ESI) m/z calcd for $\text{C}_{22}\text{H}_{25}\text{N}_2\text{O}_3^+$ ($\text{M}+\text{H}$) $^+$ 365.1860, found 365.1859.

***(Z)*-3-((*tert*-butylamino)methylene)-4-oxo-N-((*S*)-1-phenylethyl)chromane-2-carboxamide**



5p (*dr* =1:1), 62mg, yellow solid, 55% (EA/Hex = 20%, *R_f* = 0.3), ¹H NMR (400 MHz, CDCl₃) δ 10.79 (d, *J* = 12.9 Hz, 1H), 10.70 (d, *J* = 12.4 Hz, 1H), 7.99 (d, *J* = 7.7 Hz, 1H), 7.90 – 7.86 (m, 1H), 7.67 (s, 1H), 7.54 (s, 1H), 7.45 (d, *J* = 8.5 Hz, 1H), 7.42 (s, 1H), 7.33 (d, *J* = 7.1 Hz, 4H), 7.28 (s, 2H), 7.22 (d, *J* = 7.7 Hz, 2H), 7.19 – 7.14 (m, 3H), 7.05 (dd, *J* = 17.2, 7.7 Hz, 2H), 6.96 – 6.91 (m, 1H), 5.29 (d, *J* = 14.8 Hz, 2H), 5.07 – 4.99 (m, 2H), 1.46 (s, 3H), 1.34 (s, 3H), 1.23 (s, 9H). ¹³C NMR (101 MHz, CDCl₃) δ 181.17, 179.02, 169.28, 168.94, 158.21, 156.45, 154.77, 149.06, 148.34, 134.22, 133.44, 128.84, 128.54, 128.40, 128.38, 127.49, 126.11, 126.05, 125.61, 125.47, 125.43, 124.02, 123.87, 122.38, 117.32, 116.52, 116.46, 78.42, 78.22, 52.81, 52.48, 48.76, 48.53, 29.99, 29.45, 22.00, 21.87. HRMS (ESI) *m/z* calcd for C₂₃H₂₇N₂O₃⁺ (*M*+*H*)⁺ 379.2016, found 379.2015.


(Z)-3-((tert-butylamino)methylene)-N-cyclohexyl-4-oxochromane-2-carboxamide



5q, 41mg, yellow solid, 39% (EA/Hex = 20%, *R_f* = 0.3), ¹H NMR (400 MHz, CDCl₃) δ 10.76 (d, *J* = 13.2 Hz, 1H), 8.18 (s, 1H), 7.37 (dd, *J* = 17.8, 8.6 Hz, 2H), 7.04 (t, *J* = 7.5 Hz, 1H), 6.94 (d, *J* = 8.2 Hz, 1H), 6.32 (d, *J* = 6.8 Hz, 1H), 5.26 (s, 1H), 3.70 (d, *J* = 12.7 Hz, 1H), 1.75 – 1.65 (m, 3H), 1.59 – 1.48 (m, 3H), 1.33 (s, 9H), 1.20 – 1.10 (m, 4H). ¹³C NMR (101 MHz, CDCl₃) δ 179.19, 169.02, 155.50, 134.11, 133.73, 133.14, 126.49, 125.72, 125.17, 122.35, 118.20, 116.34, 96.20, 52.55, 48.15, 29.90, 29.54,


25.38, 24.54. HRMS (ESI) m/z calcd for $C_{21}H_{29}N_2O_3^+$ (M+H)⁺ 357.2173, found 357.2177.

***(Z)*-3-((*tert*-butylamino)methylene)-6-methyl-4-oxo-*N*-(2,4,4-trimethylpentan-2-yl)chromane-2-carboxamide**



5r, 95 mg, yellow solid, 79% (EA/Hex = 20%, R_f = 0.3), ¹H NMR (400 MHz, CDCl₃) δ 10.76 (d, J = 13.2 Hz, 1H), 7.65 (s, 1H), 7.30 (d, J = 13.4 Hz, 1H), 7.16 (d, J = 8.3 Hz, 1H), 6.81 (d, J = 8.3 Hz, 1H), 6.37 (s, 1H), 5.10 (d, J = 0.9 Hz, 1H), 2.29 (s, 3H), 1.66 (s, 2H), 1.36 (d, J = 7.9 Hz, 6H), 1.33 (d, J = 1.7 Hz, 9H), 0.89 (d, J = 1.4 Hz, 9H). ¹³C NMR (101 MHz, CDCl₃) δ 179.47, 168.79, 154.42, 148.70, 134.18, 131.67, 126.42, 123.31, 116.14, 95.88, 78.42, 55.12, 52.73, 51.92, 31.54, 31.48, 31.35, 29.99, 29.14, 28.78, 28.67, 20.57. HRMS (ESI) m/z calcd for $C_{24}H_{37}N_2O_3^+$ (M+H)⁺ 401.2799, found 401.2800.


***(Z)*-3-((*tert*-butylamino)methylene)-6,8-dichloro-4-oxo-*N*-(2,4,4-trimethylpentan-2-yl)chromane-2-carboxamide**



5s, 113 mg, yellow solid, 83% (EA/Hex = 20%, R_f = 0.3), ¹H NMR (400 MHz, CDCl₃) δ 9.63 (d, J = 2.9 Hz, 1H), 7.73 (d, J = 1.2 Hz, 1H), 7.49 (d, J = 3.3 Hz, 1H), 7.41 (s, 1H), 7.34 (d, J = 5.1 Hz, 1H), 5.18 (s, 1H), 1.67 (s, 2H) 1.46 (s, 6H), 1.36 (s,


9H), 1.00 (s, 9H). ^{13}C NMR (101 MHz, CDCl_3) δ 176.12, 167.96, 156.12, 150.34, 133.93, 132.41, 129.13, 124.82, 123.17, 78.80, 51.21, 31.75, 31.43, 29.92, 29.35. HRMS (ESI) m/z calcd for $\text{C}_{23}\text{H}_{33}\text{Cl}_2\text{N}_2\text{O}_3^+$ ($\text{M}+\text{H}$) $^+$ 455.1863, found 455.1863.

***(Z)*-3-((*tert*-butylamino)methylene)-6-chloro-4-oxo-*N*-(2,4,4-trimethylpentan-2-yl)chromane-2-carboxamide**



5t, 89mg, yellow solid, 71% (EA/Hex = 20%, R_f = 0.3), ^1H NMR (400 MHz, CDCl_3) δ 10.83 (d, J = 12.7 Hz, 1H), 7.84 (s, 1H), 7.34 (dd, J = 17.9, 11.1 Hz, 2H), 6.89 (d, J = 8.2 Hz, 1H), 6.34 (s, 1H), 5.17 (s, 1H), 1.70 (s, 2H), 1.40 (d, J = 6.9 Hz, 6H), 1.36 (s, 9H), 0.93 (s, 9H). ^{13}C NMR (101 MHz, CDCl_3) δ 177.75, 168.31, 154.93, 149.31, 133.10, 127.72, 126.18, 124.86, 118.01, 95.38, 78.58, 55.32, 53.07, 51.98, 31.62, 31.42, 30.00, 29.16, 28.73. HRMS (ESI) m/z calcd for $\text{C}_{23}\text{H}_{34}\text{ClN}_2\text{O}_3^+$ ($\text{M}+\text{H}$) $^+$ 421.2252, found 421.2250.


***(Z)*-*N*-(*tert*-butyl)-3-((cyclopropylamino)methylene)-4-oxochromane-2-carboxamide**



5u, 44 mg, light green solid, 47% (EA/Hex = 30%, R_f = 0.35), ^1H NMR (400 MHz, CDCl_3) δ 10.32 (d, J = 12.3 Hz, 1H), 7.87 (d, J = 7.8 Hz, 1H), 7.42 – 7.35 (m, 1H), 7.20 (s, 1H), 7.05 (t, J = 7.5 Hz, 1H), 6.94 (d, J = 8.2 Hz, 1H), 6.28 (s, 1H), 5.14 (s, 1H), 2.82 (s, 1H), 1.30 (s, 9H), 0.77 – 0.73 (m, 2H), 0.71 (dd, J = 4.8, 3.5 Hz, 2H). ^{13}C NMR (100 MHz, CDCl_3) δ 169.18, 156.97, 153.18, 134.06, 127.08, 123.87,


122.72, 116.81, 97.28, 78.70, 51.62, 29.78, 28.96, 6.93. HRMS (ESI) m/z calcd for $C_{18}H_{23}N_2O_3^+$ ($M+H$) $^+$ 315.1703, found 315.1701.

***(Z)*-3-((butylamino)methylene)-N-(2,6-dimethylphenyl)-4-oxochromane-2-carboxamide**



5v, 24 mg, white solid, 21% (EA/Hex = 30%, R_f = 0.3), 1H NMR (400 MHz, $CDCl_3$) δ 10.45 (d, J = 12.7 Hz, 1H), 7.94 (d, J = 7.9 Hz, 1H), 7.65 (s, 1H), 7.40 (t, J = 7.8 Hz, 1H), 7.22 (d, J = 13.1 Hz, 1H), 7.08 (dd, J = 14.9, 7.5 Hz, 2H), 7.02 (d, J = 7.8 Hz, 2H), 5.47 (s, 1H), 3.29 (dd, J = 13.2, 6.6 Hz, 2H), 2.03 (s, 6H), 1.38 (dd, J = 15.0, 7.6 Hz, 2H), 1.24 (t, J = 6.7 Hz, 2H), 0.91 (t, J = 7.3 Hz, 3H). ^{13}C NMR (100 MHz, $CDCl_3$) δ 180.55, 155.51, 153.31, 151.26, 133.67, 126.59, 124.00, 122.54, 116.79, 96.79, 71.38, 62.59, 49.21, 32.85, 30.00, 19.66, 13.59. HRMS (ESI) m/z calcd for $C_{23}H_{27}N_2O_3^+$ ($M+H$) $^+$ 379.2016, found 379.2021.


***(Z)*-4-oxo-3-(pyrrolidin-1-ylmethylene)-N-(2,4,4-trimethylpentan-2-yl)chromane-2-carboxamide**



5w, 72 mg, light green solid, 63% (EA/Hex = 40%, R_f = 0.2), 1H NMR (400 MHz, $CDCl_3$) δ 8.08 (s, 1H), 7.95 (d, J = 7.6 Hz, 1H), 7.42 – 7.34 (m, 1H), 7.06 – 6.98 (m, 1H), 6.92 (d, J = 8.4 Hz, 1H), 6.08 (s, 1H), 5.77 (s, 1H), 3.86 (s, 2H), 3.53 (s, 2H), 1.96 (s, 2H), 1.21 (s, 6H), 0.97 (d, J = 12.2 Hz, 2H), 0.84 (d, J = 13.2 Hz, 2H), 0.76 (s, 9H). ^{13}C NMR (101 MHz, $CDCl_3$) δ 178.30, 169.90, 156.82, 146.98, 133.64, 127.89,


122.10, 116.02, 75.67, 55.11, 51.27, 31.37, 31.14, 29.66, 29.35, 28.84. HRMS (ESI) m/z calcd for $C_{23}H_{33}N_2O_3^+$ (M+H)⁺ 385.2486, found 385.2486.

3-((4-methoxypiperidin-1-yl)methylene)-4-oxo-N-(2,4,4-trimethylpentan-2-yl)chromane-2-carboxamide




5x, 84 mg, light green solid, 66% (EA/Hex = 40%, R_f = 0.2), ¹H NMR (400 MHz, CDCl₃) δ 7.93 (d, J = 7.5 Hz, 1H), 7.82 (s, 1H), 7.38 (t, J = 7.6 Hz, 1H), 7.02 (t, J = 7.5 Hz, 1H), 6.92 (d, J = 8.2 Hz, 1H), 6.10 (s, 1H), 5.77 (s, 1H), 3.87 – 3.68 (m, 2H), 3.59 – 3.41 (m, 3H), 3.35 (s, 3H), 1.94 (dd, J = 16.1, 9.7 Hz, 2H), 1.75 (d, J = 11.4 Hz, 2H), 1.24 (s, 2H), 1.23 (d, J = 8.4 Hz, 6H), 0.77 (s, 9H). ¹³C NMR (101 MHz, CDCl₃) δ 178.83, 169.39, 149.65, 133.75, 127.83, 122.17, 116.11, 97.40, 75.90, 73.92, 55.78, 55.18, 51.21, 31.49, 31.39, 31.30, 31.21, 31.13, 30.71, 29.67, 29.36, 28.87, 28.78. HRMS (ESI) m/z calcd for $C_{25}H_{37}N_2O_4^+$ (M+H)⁺ 429.2478, found 429.2477.

3-(morpholinomethylene)-4-oxo-N-(2,4,4-trimethylpentan-2-yl)chromane-2-carboxamide




5y, 69 mg, light green solid, 58% (EA/Hex = 40%, Rf = 0.2), ¹H NMR (400 MHz, CDCl₃) δ 7.94 (d, *J* = 7.7 Hz, 1H), 7.76 (s, 1H), 7.40 (t, *J* = 7.8 Hz, 1H), 7.03 (t, *J* = 7.5 Hz, 1H), 6.93 (d, *J* = 8.2 Hz, 1H), 6.10 (s, 1H), 5.76 (s, 1H), 3.86 – 3.74 (m, 6H), 3.49 (dd, *J* = 8.5, 5.1 Hz, 2H), 1.24 (s, 2H), 1.22 (s, 6H), 0.76 (s, 9H). ¹³C NMR (101 MHz, CDCl₃) δ 178.92, 169.34, 157.19, 149.62, 134.02, 127.94, 123.17, 122.30, 116.08, 98.14, 75.74, 66.53, 55.24, 51.53, 51.23, 31.49, 31.38, 31.13, 29.38, 28.84. HRMS (ESI) *m/z* calcd for C₂₃H₃₃N₂O₄⁺ (M+H)⁺ 401.2435, found 401.2330.

3-formyl-4-oxo-N-(2,4,4-trimethylpentan-2-yl)-4H-chromene-2-carboxamide



11, 28 mg, white solid, 42% (EA/Hex = 25%, Rf = 0.25), ¹H NMR (400 MHz, CDCl₃) δ 10.36 (s, 1H), 8.34 (dd, *J* = 8.0, 1.6 Hz, 1H), 7.83 (ddd, *J* = 8.7, 7.3, 1.7 Hz, 1H), 7.59 (td, *J* = 7.7, 1.0 Hz, 1H), 7.51 – 7.43 (m, 1H), 2.11 (s, 2H), 1.70 (s, 6H), 0.86 (s, 9H). ¹³C NMR (100 MHz, CDCl₃) δ 187.96, 175.76, 156.73, 155.59, 146.04, 135.85, 127.52, 126.42, 124.62, 121.18, 118.24, 66.59, 54.62, 31.66, 30.72, 29.35. HRMS (ESI) *m/z* calcd for C₂₃H₂₇N₂O₃⁺ (M+H)⁺ 330.1700, found 330.1705.



(Z)-3-((tert-butylamino)methylene)-N-(1-(4-chlorophenyl)cyclopropane-1-carbonyl)-N-(2,6-dimethylphenyl)-4-oxochromane-2-carboxamide





13, 139 mg, light green solid, 83% (EA/Hex = 20%, Rf = 0.3), ¹H NMR (400 MHz, CDCl₃) δ 10.45 (d, *J* = 13.4 Hz, 1H), 7.75 (dd, *J* = 7.8, 1.6 Hz, 1H), 7.32 (ddd, *J* = 8.2, 7.3, 1.8 Hz, 1H), 7.07 – 6.95 (m, 2H), 6.97 – 6.87 (m, 4H), 6.68 (d, *J* = 7.3 Hz, 1H),

6.62 (d, $J = 8.3$ Hz, 2H), 6.05 (s, 1H), 1.92 (s, 2H), 1.91 – 1.82 (m, 1H), 1.55 – 1.49 (m, 1H), 1.37 (s, 9H), 1.23 – 1.13 (m, 1H), 0.82 (ddd, $J = 9.4, 7.2, 3.9$ Hz, 1H). ^{13}C NMR (100 MHz, CDCl_3) δ 180.52, 177.01, 158.74, 148.86, 137.36, 136.73, 136.61, 135.01, 133.93, 132.67, 130.79, 128.82, 128.46, 127.97, 125.93, 123.13, 121.35, 117.04, 95.91, 79.48, 52.80, 32.33, 30.09, 18.26, 18.06, 17.71. HRMS (ESI) m/z calcd for $\text{C}_{33}\text{H}_{34}\text{ClN}_2\text{O}_4^+$ ($\text{M}+\text{H}$) $^+$ 557.2202, found 557.2201.



^1H NMR and ^{13}C NMR spectrum of **5a**





^1H NMR and ^{13}C NMR spectrum of **5b**





^1H NMR and ^{13}C NMR spectrum of **5c**





^1H NMR and ^{13}C NMR spectrum of **5d**





^1H NMR and ^{13}C NMR spectrum of **5e**





^1H NMR and ^{13}C NMR spectrum of **5f**





^1H NMR and ^{13}C NMR spectrum of **5g**





^1H NMR and ^{13}C NMR spectrum of **5h**





^1H NMR and ^{13}C NMR spectrum of **5i**





^1H NMR and ^{13}C NMR spectrum of **5j**





^1H NMR and ^{13}C NMR spectrum of **5k**





^1H NMR and ^{13}C NMR spectrum of **51**





^1H NMR and ^{13}C NMR spectrum of **5m**





^1H NMR and ^{13}C NMR spectrum of **5n**





^1H NMR and ^{13}C NMR spectrum of **50**





^1H NMR and ^{13}C NMR spectrum of **5p**





^1H NMR and ^{13}C NMR spectrum of **5q**





^1H NMR and ^{13}C NMR spectrum of **5r**





^1H NMR and ^{13}C NMR spectrum of **5s**





^1H NMR and ^{13}C NMR spectrum of **5t**





^1H NMR and ^{13}C NMR spectrum of **5u**





^1H NMR and ^{13}C NMR spectrum of **5v**





^1H NMR and ^{13}C NMR spectrum of **5w**





^1H NMR and ^{13}C NMR spectrum of **5x**





^1H NMR and ^{13}C NMR spectrum of **5y**



^1H NMR and ^{13}C NMR spectrum of **11**



^1H NMR and ^{13}C NMR spectrum of **13**



checkCIF/PLATON report

Structure factors have been supplied for datablock(s) A

THIS REPORT IS FOR GUIDANCE ONLY. IF USED AS PART OF A REVIEW PROCEDURE FOR PUBLICATION, IT SHOULD NOT REPLACE THE EXPERTISE OF AN EXPERIENCED CRYSTALLOGRAPHIC REFEREE.

No syntax errors found. CIF dictionary Interpreting this report

Datablock: A

Bond precision:	C-C = 0.0060 A	Wavelength=0.71073	
Cell:	a=10.3143(11)	b=13.9869(12)	c=20.0442(9)
	alpha=90	beta=99.155(18)	gamma=90
Temperature:	296 K		
	Calculated	Reported	
Volume	2854.8(4)	2854.8(4)	
Space group	P 21/c	P 1 21/c 1	
Hall group	-P 2ybc	-P 2ybc	
Moiety formula	C33 H33 Cl N2 O4	C33 H33 Cl N2 O4	
Sum formula	C33 H33 Cl N2 O4	C33 H33 Cl N2 O4	
Mr	557.06	557.09	
Dx,g cm-3	1.296	1.296	
Z	4	4	
Mu (mm-1)	0.175	0.175	
F000	1176.0	1177.1	
F000'	1177.09		
h,k,lmax	12,16,23	12,16,23	
Nref	5029	5020	
Tmin,Tmax	0.952,0.966	0.952,0.966	
Tmin'	0.952		

Correction method= # Reported T Limits: Tmin=0.952 Tmax=0.966
AbsCorr = NONE

Data completeness= 0.998 Theta(max)= 25.000

R(reflections)= 0.0607(2297) wR2(reflections)= 0.1398(5020)

S = 1.110 Npar= 361

The following ALERTS were generated. Each ALERT has the format

test-name_ALERT_alert-type_alert-level.

Click on the hyperlinks for more details of the test.

● **Alert level C**

ABSTY03_ALERT_1_C The _exptl_absorpt_correction_type has been given as none.
However values have been given for Tmin and Tmax. Remove
these if an absorption correction has not been applied.
From the CIF: _exptl_absorpt_correction_T_min 0.952
From the CIF: _exptl_absorpt_correction_T_max 0.966

PLAT026_ALERT_3_C	Ratio Observed / Unique Reflections (too) Low ..	46%	Check
PLAT230_ALERT_2_C	Hirshfeld Test Diff for C21 --C29 .	5.3	s.u.
PLAT241_ALERT_2_C	High 'MainMol' Ueq as Compared to Neighbors of	C9	Check
PLAT241_ALERT_2_C	High 'MainMol' Ueq as Compared to Neighbors of	C26	Check
PLAT242_ALERT_2_C	Low 'MainMol' Ueq as Compared to Neighbors of	C1	Check
PLAT242_ALERT_2_C	Low 'MainMol' Ueq as Compared to Neighbors of	C30	Check
PLAT334_ALERT_2_C	Small Aver. Benzene C-C Dist C23 -C28	1.37	Ang.
PLAT340_ALERT_3_C	Low Bond Precision on C-C Bonds	0.00597	Ang.
PLAT905_ALERT_3_C	Negative K value in the Analysis of Variance ...	-1.909	Report
PLAT911_ALERT_3_C	Missing FCF Refl Between Thmin & STh/L= 0.595	9	Report
PLAT978_ALERT_2_C	Number C-C Bonds with Positive Residual Density.	0	Info

● **Alert level G**

PLAT066_ALERT_1_G	Predicted and Reported Tmin&Tmax Range Identical	?	Check
PLAT073_ALERT_1_G	H-atoms ref, but _hydrogen_treatment Reported as	constr	Check
PLAT380_ALERT_4_G	Incorrectly? Oriented X(sp2)-Methyl Moiety	C13	Check
PLAT380_ALERT_4_G	Incorrectly? Oriented X(sp2)-Methyl Moiety	C18	Check
PLAT793_ALERT_4_G	Model has Chirality at C20 (Centro SPGR)	S	Verify
PLAT883_ALERT_1_G	No Info/Value for _atom_sites_solution_primary .	Please	Do !
PLAT933_ALERT_2_G	Number of OMIT Records in Embedded .res File ...	5	Note
PLAT960_ALERT_3_G	Number of Intensities with I < - 2*sig(I) ...	17	Check
PLAT983_ALERT_1_G	The Cl-f"= 0.1603 Deviates from IT-Value =	0.1585	Check

- 0 **ALERT level A** = Most likely a serious problem - resolve or explain
0 **ALERT level B** = A potentially serious problem, consider carefully
12 **ALERT level C** = Check. Ensure it is not caused by an omission or oversight
9 **ALERT level G** = General information/check it is not something unexpected
- 5 ALERT type 1 CIF construction/syntax error, inconsistent or missing data
8 ALERT type 2 Indicator that the structure model may be wrong or deficient
5 ALERT type 3 Indicator that the structure quality may be low
3 ALERT type 4 Improvement, methodology, query or suggestion
0 ALERT type 5 Informative message, check
-
-

It is advisable to attempt to resolve as many as possible of the alerts in all categories. Often the minor alerts point to easily fixed oversights, errors and omissions in your CIF or refinement strategy, so attention to these fine details can be worthwhile. In order to resolve some of the more serious problems it may be necessary to carry out additional measurements or structure refinements. However, the purpose of your study may justify the reported deviations and the more serious of these should normally be commented upon in the discussion or experimental section of a paper or in the "special_details" fields of the CIF. checkCIF was carefully designed to identify outliers and unusual parameters, but every test has its limitations and alerts that are not important in a particular case may appear. Conversely, the absence of alerts does not guarantee there are no aspects of the results needing attention. It is up to the individual to critically assess their own results and, if necessary, seek expert advice.

Publication of your CIF in IUCr journals

A basic structural check has been run on your CIF. These basic checks will be run on all CIFs submitted for publication in IUCr journals (*Acta Crystallographica*, *Journal of Applied Crystallography*, *Journal of Synchrotron Radiation*); however, if you intend to submit to *Acta Crystallographica Section C* or *E* or *IUCrData*, you should make sure that full publication checks are run on the final version of your CIF prior to submission.

Publication of your CIF in other journals

Please refer to the *Notes for Authors* of the relevant journal for any special instructions relating to CIF submission.

PLATON version of 17/03/2019; check.def file version of 04/03/2019

